Genotyped Human Liver Microsomes
View Products CYP3A5 Genotype
XenoTech's genotyped products include human liver microsomes characterized for three CYP3A5 allelic categories, high activity (*1/*1), moderate activity (*1/*3) and no activity (*3/*3).
DESCRIPTIONPACKAGINGCHARACTERIZATION PROVIDEDSAFETY, HANDLING AND STORAGEPRODUCTSDESCRIPTION
Members of the CYP3A family are the most abundant CYP enzymes in the human liver and intestine, influencing circulating steroid levels and responding to half of all oxidatively metabolized drugs. When it is present, CYP3A5 can represent up to 50% of the total CYP3A protein in liver microsomes, suggesting a potentially important role in the clearance of CYP3A substrates.
There are substantial CYP3A expression differences between individuals, which contributes greatly to variation in oral bioavailability and systemic clearance of CYP3A substrates. There are also pronounced inter-racial differences in CYP3A5 allelic frequency.
Allele |
African American |
Asian |
Caucasian |
Hispanic |
*1 |
0.45 – 0.73 |
0.15 – 0.38 |
0.05 – 0.15 |
0.25 |
*3 |
0.06 – 0.50 |
0.60 – 0.76 |
0.82 – 0.96 |
0.46 – 0.71 |
Adapted from Thompson, et al. 2004, Wang, et al. 2006, Kuehl, et al. 2001 and Lamba, et al. 2002.
Human livers are screened and characterized by genotype in a combined approach with both PCR and Western blot techniques to distinguish between three CYP3A5 allelic categories.
Return to Top
PACKAGING
Concentration: 20 mg/mL
Suspension buffer: 250 mM sucrose
Return to Top
CHARACTERIZATION PROVIDED
- Genotype
- Specific content of cytochrome P450
- Specific content of cytochrome b5
- NADPH-cytochrome c reductase activity
- CYP1A2 Phenacetin O-dealkylation
- CYP2A6 Coumarin 7-hydroxylation
- CYP2B6 Bupropion hydroxylation
- CYP2C8 Amodiaquine N-dealkylation
- CYP2C9 Diclofenac 4´-hydroxylation
- CYP2C19 S-Mephenytoin 4´-hydroxylation
- CYP2D6 Dextromethorphan O-demethylation
- CYP2E1 Chlorzoxazone 6-hydroxylation
- CYP3A4/5 Testosterone 6β-hydroxylation
- CYP3A4/5 Midazolam 1´-hydroxylation
- CYP4A11 Lauric acid 12-hydroxylation
- Donor information (age, ethnicity, gender, cause of death and infectious disease status)
Return to TopSAFETY, HANDLING AND STORAGE
Informed Consent Statement
A single organization regulates and oversees the use of human tissue intended for transplantation in the United States, namely the United Network for Organ Sharing (UNOS). Organ donors may elect to have their organs used either for transplantation only, or for transplantation or research. Thus, the donor (or the donor's family) has the right to prevent the use of the donor's organs for research. Regardless of the use of donated organs, no compensation is given to the donor’s family; any such compensation is illegal in the United States. In those cases where donors (or family members) elect to withhold organs from research uses, any organs that cannot be transplanted are discarded.
XenoTech receives hepatic, renal, intestinal, pulmonary, and other human tissue from various regional organ procurement organizations (OPOs) that obtain organs approved for research use. Regulations in the United States require that, regardless whether the organ is intended for transplantation or research purposes, the organ donor's identity be treated as highly confidential information. Organ procurement organizations maintain the informed consent records from each donor, and our Standard Operating Procedure requires that XenoTech personnel confirm the existence of informed consent for research purposes, prior to transport of organs to XenoTech. This procedure is intended to ensure that XenoTech manufactures human-derived products only when informed consent has been granted for research use of those specific organs. XenoTech does not, and, in consideration of confidentiality, cannot obtain the informed consent records from these organizations.
All human tissue accepted by XenoTech has been tested for the possible presence of various infectious diseases, and XenoTech does not accept human-derived material unless the donor has tested negative (non-reactive) for RPR, HIVAb, HTLVAb, HBsAg and HCVAb. All human tissue is also tested for CMVAb. However, due to the widespread (nearly ubiquitous) appearance of CMV in the population, and its relative insignificance as an infectious agent, tissues from donors reactive for CMVAb are accepted. The serology status of each donor is typically determined by ELISA by the organ procurement hospital.
XenoTech does not deal directly with - nor does it make any direct payments to - the surgeons who procure organs or the medical institutions where they work.
Caution: In the case of human tissue, XenoTech accepts only non-transplantable tissue from donors who test negative for HIV 1 and 2, HTLV, and Hepatitis B and C. However, as a precaution, all human-derived samples should be regarded as a potential biohazard and should be stored, handled and discarded accordingly. Cellular and subcellular fractions are intended for in vitro use only.
Return to TopPRODUCTS
Product No. |
Product |
Amount |
H3A5.HA |
CYP3A5 High Activity (*1/*1) |
0.5 mL at 20 mg/mL |
H3A5.MA |
CYP3A5 Moderate Activity (*1/*3) |
0.5 mL at 20 mg/mL |
H3A5.NA |
CYP3A5 No Activity (*3/*3) |
0.5 mL at 20 mg/mL |
Return to Top Order Fax: 913.227.7171
Order E-mail: info@xenotechllc.com
Call 877.588.7530 (toll-free US and Canada) for pricing and availability.
If ordering outside of North America, please see our Distributor information.